Expression Levels of the ABCG2 Multidrug Transporter in Human Erythrocytes Correspond to Pharmacologically Relevant Genetic Variations

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Kasza, Ildikó ^a,b   Várady, György ^a,b,e   Andrikovics, Hajnalka ^c   Koszarska, Magdalena ^c   Tordai, Attila ^c   Scheffer, George L ^d   Németh, Adrienn ^b   Szakács, Gergely ^e   Sarkadi, Balázs ^a,c,e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b CellPharma Kft   (Hungary)

^c Hungarian National Blood Transfusion Service   (Hungary)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MEMBRANE PROTEIN; URIC ACID;

ABCG2 GENE; ALLELE; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; ERYTHROCYTE; FLOW CYTOMETRY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; METABOLISM; NONSENSE MUTATION; PHARMACOKINETICS; PROTEIN EXPRESSION; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; URIC ACID METABOLISM; WILD TYPE;

ATP-BINDING CASSETTE TRANSPORTERS; CODON, NONSENSE; ERYTHROCYTES; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MUTATION, MISSENSE; NEOPLASM PROTEINS;

EID: 84869208650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048423     Document Type: Article

References (50)

1. Alexandre BM, (2010) Proteomic mining of the red blood cell: focus on the membrane proteome. Expert Rev Proteomics 7: 165-168.
2. Goodman SR, Kurdia A, Ammann L, Kakhniashvili D, Daescu O, (2007) The human red blood cell proteome and interactome. Exp Biol Med (Maywood) 232: 1391-1408.
3. Pasini EM, Kirkegaard M, Mortensen P, Lutz HU, Thomas AW, et al. (2006) In-depth analysis of the membrane and cytosolic proteome of red blood cells. Blood 108: 791-801.
4. Pasini EM, Lutz HU, Mann M, Thomas AW, (2010) Red blood cell (RBC) membrane proteomics-Part I: Proteomics and RBC physiology. J Proteomics 73: 403-420.
5. Allen JD, Schinkel AH, (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1: 427-434.
6. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15665-15670.
7. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99: 15649-15654.
8. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, et al. (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279: 24218-24225.
9. Krishnamurthy P, Schuetz JD, (2006) Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46: 381-410.
10. Robey RW, Polgar O, Deeken J, To KW, Bates SE, (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26: 39-57.
11. Sarkadi B, Homolya L, Szakacs G, Varadi A, (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.
12. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B, (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379-393.
13. Akasaka K, Kaburagi T, Yasuda S, Ohmori K, Abe K, et al. (2010) Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 66: 691-698.
14. Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, et al. (2009) ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132: 2517-2530.
15. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, et al. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98: 1739-1742.
16. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, et al. (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80: 192-201.
17. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, et al. (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 1: 696-702.
18. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1: 611-616.
19. Ishikawa T, Nakagawa H, Hagiya Y, Nonoguchi N, Miyatake S, et al. (2010) Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. Adv Pharmacol Sci 2010: 587306.
20. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, et al. (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6: 432-438.
21. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, et al. (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76: 38-44.
22. Tamura A, Onishi Y, An R, Koshiba S, Wakabayashi K, et al. (2007) In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab Pharmacokinet 22: 428-440.
23. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, et al. (2008) Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128: 1925-1929.
24. Basseville A, Bates SE, (2011) Gout, genetics and ABC transporters. F1000 Biol Rep 3: 23.
25. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, et al. (2012) Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3: 764.
26. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, et al. (2009) Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 1: 5ra11.
27. Robey RW, Ierano C, Zhan Z, Bates SE, (2011) The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 12: 595-608.
28. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, et al. (2010) Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 3: 523-530.
29. Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Nemet K, et al. (2006) The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett 234: 62-72.
30. Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, et al. (2009) Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res 26: 469-479.
31. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, et al. (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21: 1895-1903.
32. Mizuarai S, Aozasa N, Kotani H, (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109: 238-246.
33. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, et al. (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56: 161-172.
34. Nakagawa H, Toyoda Y, Wakabayashi-Nakao K, Tamaki H, Osumi M, et al. (2011) Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts. J Pharm Sci 100: 3602-3619.
35. de Wolf CJ, Yamaguchi H, van der Heijden I, Wielinga PR, Hundscheid SL, et al. (2007) cGMP transport by vesicles from human and mouse erythrocytes. Febs J 274: 439-450.
36. Leimanis ML, Georges E, (2007) ABCG2 membrane transporter in mature human erythrocytes is exclusively homodimer. Biochem Biophys Res Commun 354: 345-350.
37. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458-3464.
38. Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, et al. (2005) Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105: 2571-2576.
39. Saison C, Helias V, Ballif BA, Peyrard T, Puy H, et al. (2012) Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat Genet 44: 174-177.
40. Zelinski T, Coghlan G, Liu XQ, Reid ME, (2012) ABCG2 null alleles define the Jr(a-) blood group phenotype. Nat Genet 44: 131-132.
41. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, et al. (2000) Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60: 2589-2593.
42. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, et al. (2002) Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198: 213-219.
43. Caride AJ, Filoteo AG, Enyedi A, Verma AK, Penniston JT, (1996) Detection of isoform 4 of the plasma membrane calcium pump in human tissues by using isoform-specific monoclonal antibodies. Biochem J 316 (Pt 1): 353-359.
44. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, et al. (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158: 1153-1164.
45. Fischer S, Lakatos PL, Lakatos L, Kovacs A, Molnar T, et al. (2007) ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases. Scand J Gastroenterol 42: 726-733.
46. Ozvegy-Laczka C, Laczko R, Hegedus C, Litman T, Varady G, et al. (2008) Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem 283: 26059-26070.
47. Cusatis G, Sparreboom A, (2008) Pharmacogenomic importance of ABCG2. Pharmacogenomics 9: 1005-1009.
48. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101.
49. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, et al. (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44: 152-167.
50. Li N, Palandra J, Nemirovskiy OV, Lai Y, (2009) LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal Chem 81: 2251-2259.